Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma

Ali H. Zaidi, Vanathi Gopalakrishnan, Pashtoon M. Kasi, Xuemei Zeng, Usha Malhotra, Jeya Balasubramanian, Shyam Visweswaran, Mai Sun, Melanie S. Flint, Jon M. Davison, Brian L. Hood, Thomas P. Conrads, Jacques J. Bergman, William L. Bigbee, Blair A. Jobe

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

BACKGROUND: Esophageal adenocarcinoma (EAC) is associated with a dismal prognosis. The identification of cancer biomarkers can advance the possibility for early detection and better monitoring of tumor progression and/or response to therapy. The authors present results from the development of a serum-based, 4-protein (biglycan, myeloperoxidase, annexin-A6, and protein S100-A9) biomarker panel for EAC.

METHODS: A vertically integrated, proteomics-based biomarker discovery approach was used to identify candidate serum biomarkers for the detection of EAC. Liquid chromatography-tandem mass spectrometry analysis was performed on formalin-fixed, paraffin-embedded tissue samples that were collected from across the Barrett esophagus (BE)-EAC disease spectrum. The mass spectrometry-based spectral count data were used to guide the selection of candidate serum biomarkers. Then, the serum enzyme-linked immunosorbent assay data were validated in an independent cohort and were used to develop a multiparametric riskassessment model to predict the presence of disease.

RESULTS: With a minimum threshold of 10 spectral counts, 351 proteins were identified as differentially abundant along the spectrum of Barrett esophagus, high-grade dysplasia, and EAC (P<.05). Eleven proteins from this data set were then tested using enzyme-linked immunosorbent assays in serum samples, of which 5 proteins were significantly elevated in abundance among patients who had EAC compared with normal controls, which mirrored trends across the disease spectrum present in the tissue data. By using serum data, a Bayesian rule-learning predictive model with 4 biomarkers was developed to accurately classify disease class; the cross-validation results for the merged data set yielded accuracy of 87% and an area under the receiver operating characteristic curve of 93%.

CONCLUSIONS: Serum biomarkers hold significant promise for the early, noninvasive detection of EAC.

Original languageEnglish (US)
Pages (from-to)3902-3913
Number of pages12
JournalCancer
Volume120
Issue number24
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Annexin A6
Biglycan
S100 Proteins
Adenosine Monophosphate
Peroxidase
Blood Proteins
Adenocarcinoma
Biomarkers
Serum
Barrett Esophagus
Proteins
Enzyme-Linked Immunosorbent Assay
Esophageal Diseases
Tumor Biomarkers
Tandem Mass Spectrometry
ROC Curve
Liquid Chromatography
Paraffin
Proteomics
Formaldehyde

Keywords

  • Biomarker
  • Early detection
  • Esophageal adenocarcinoma
  • Monitoring
  • Protein
  • Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Zaidi, A. H., Gopalakrishnan, V., Kasi, P. M., Zeng, X., Malhotra, U., Balasubramanian, J., ... Jobe, B. A. (2014). Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. Cancer, 120(24), 3902-3913. https://doi.org/10.1002/cncr.28963

Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. / Zaidi, Ali H.; Gopalakrishnan, Vanathi; Kasi, Pashtoon M.; Zeng, Xuemei; Malhotra, Usha; Balasubramanian, Jeya; Visweswaran, Shyam; Sun, Mai; Flint, Melanie S.; Davison, Jon M.; Hood, Brian L.; Conrads, Thomas P.; Bergman, Jacques J.; Bigbee, William L.; Jobe, Blair A.

In: Cancer, Vol. 120, No. 24, 01.12.2014, p. 3902-3913.

Research output: Contribution to journalArticle

Zaidi, AH, Gopalakrishnan, V, Kasi, PM, Zeng, X, Malhotra, U, Balasubramanian, J, Visweswaran, S, Sun, M, Flint, MS, Davison, JM, Hood, BL, Conrads, TP, Bergman, JJ, Bigbee, WL & Jobe, BA 2014, 'Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma', Cancer, vol. 120, no. 24, pp. 3902-3913. https://doi.org/10.1002/cncr.28963
Zaidi, Ali H. ; Gopalakrishnan, Vanathi ; Kasi, Pashtoon M. ; Zeng, Xuemei ; Malhotra, Usha ; Balasubramanian, Jeya ; Visweswaran, Shyam ; Sun, Mai ; Flint, Melanie S. ; Davison, Jon M. ; Hood, Brian L. ; Conrads, Thomas P. ; Bergman, Jacques J. ; Bigbee, William L. ; Jobe, Blair A. / Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. In: Cancer. 2014 ; Vol. 120, No. 24. pp. 3902-3913.
@article{2cdd84b37913415aaaa25ab558860ef4,
title = "Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma",
abstract = "BACKGROUND: Esophageal adenocarcinoma (EAC) is associated with a dismal prognosis. The identification of cancer biomarkers can advance the possibility for early detection and better monitoring of tumor progression and/or response to therapy. The authors present results from the development of a serum-based, 4-protein (biglycan, myeloperoxidase, annexin-A6, and protein S100-A9) biomarker panel for EAC.METHODS: A vertically integrated, proteomics-based biomarker discovery approach was used to identify candidate serum biomarkers for the detection of EAC. Liquid chromatography-tandem mass spectrometry analysis was performed on formalin-fixed, paraffin-embedded tissue samples that were collected from across the Barrett esophagus (BE)-EAC disease spectrum. The mass spectrometry-based spectral count data were used to guide the selection of candidate serum biomarkers. Then, the serum enzyme-linked immunosorbent assay data were validated in an independent cohort and were used to develop a multiparametric riskassessment model to predict the presence of disease.RESULTS: With a minimum threshold of 10 spectral counts, 351 proteins were identified as differentially abundant along the spectrum of Barrett esophagus, high-grade dysplasia, and EAC (P<.05). Eleven proteins from this data set were then tested using enzyme-linked immunosorbent assays in serum samples, of which 5 proteins were significantly elevated in abundance among patients who had EAC compared with normal controls, which mirrored trends across the disease spectrum present in the tissue data. By using serum data, a Bayesian rule-learning predictive model with 4 biomarkers was developed to accurately classify disease class; the cross-validation results for the merged data set yielded accuracy of 87{\%} and an area under the receiver operating characteristic curve of 93{\%}.CONCLUSIONS: Serum biomarkers hold significant promise for the early, noninvasive detection of EAC.",
keywords = "Biomarker, Early detection, Esophageal adenocarcinoma, Monitoring, Protein, Serum",
author = "Zaidi, {Ali H.} and Vanathi Gopalakrishnan and Kasi, {Pashtoon M.} and Xuemei Zeng and Usha Malhotra and Jeya Balasubramanian and Shyam Visweswaran and Mai Sun and Flint, {Melanie S.} and Davison, {Jon M.} and Hood, {Brian L.} and Conrads, {Thomas P.} and Bergman, {Jacques J.} and Bigbee, {William L.} and Jobe, {Blair A.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1002/cncr.28963",
language = "English (US)",
volume = "120",
pages = "3902--3913",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "24",

}

TY - JOUR

T1 - Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma

AU - Zaidi, Ali H.

AU - Gopalakrishnan, Vanathi

AU - Kasi, Pashtoon M.

AU - Zeng, Xuemei

AU - Malhotra, Usha

AU - Balasubramanian, Jeya

AU - Visweswaran, Shyam

AU - Sun, Mai

AU - Flint, Melanie S.

AU - Davison, Jon M.

AU - Hood, Brian L.

AU - Conrads, Thomas P.

AU - Bergman, Jacques J.

AU - Bigbee, William L.

AU - Jobe, Blair A.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - BACKGROUND: Esophageal adenocarcinoma (EAC) is associated with a dismal prognosis. The identification of cancer biomarkers can advance the possibility for early detection and better monitoring of tumor progression and/or response to therapy. The authors present results from the development of a serum-based, 4-protein (biglycan, myeloperoxidase, annexin-A6, and protein S100-A9) biomarker panel for EAC.METHODS: A vertically integrated, proteomics-based biomarker discovery approach was used to identify candidate serum biomarkers for the detection of EAC. Liquid chromatography-tandem mass spectrometry analysis was performed on formalin-fixed, paraffin-embedded tissue samples that were collected from across the Barrett esophagus (BE)-EAC disease spectrum. The mass spectrometry-based spectral count data were used to guide the selection of candidate serum biomarkers. Then, the serum enzyme-linked immunosorbent assay data were validated in an independent cohort and were used to develop a multiparametric riskassessment model to predict the presence of disease.RESULTS: With a minimum threshold of 10 spectral counts, 351 proteins were identified as differentially abundant along the spectrum of Barrett esophagus, high-grade dysplasia, and EAC (P<.05). Eleven proteins from this data set were then tested using enzyme-linked immunosorbent assays in serum samples, of which 5 proteins were significantly elevated in abundance among patients who had EAC compared with normal controls, which mirrored trends across the disease spectrum present in the tissue data. By using serum data, a Bayesian rule-learning predictive model with 4 biomarkers was developed to accurately classify disease class; the cross-validation results for the merged data set yielded accuracy of 87% and an area under the receiver operating characteristic curve of 93%.CONCLUSIONS: Serum biomarkers hold significant promise for the early, noninvasive detection of EAC.

AB - BACKGROUND: Esophageal adenocarcinoma (EAC) is associated with a dismal prognosis. The identification of cancer biomarkers can advance the possibility for early detection and better monitoring of tumor progression and/or response to therapy. The authors present results from the development of a serum-based, 4-protein (biglycan, myeloperoxidase, annexin-A6, and protein S100-A9) biomarker panel for EAC.METHODS: A vertically integrated, proteomics-based biomarker discovery approach was used to identify candidate serum biomarkers for the detection of EAC. Liquid chromatography-tandem mass spectrometry analysis was performed on formalin-fixed, paraffin-embedded tissue samples that were collected from across the Barrett esophagus (BE)-EAC disease spectrum. The mass spectrometry-based spectral count data were used to guide the selection of candidate serum biomarkers. Then, the serum enzyme-linked immunosorbent assay data were validated in an independent cohort and were used to develop a multiparametric riskassessment model to predict the presence of disease.RESULTS: With a minimum threshold of 10 spectral counts, 351 proteins were identified as differentially abundant along the spectrum of Barrett esophagus, high-grade dysplasia, and EAC (P<.05). Eleven proteins from this data set were then tested using enzyme-linked immunosorbent assays in serum samples, of which 5 proteins were significantly elevated in abundance among patients who had EAC compared with normal controls, which mirrored trends across the disease spectrum present in the tissue data. By using serum data, a Bayesian rule-learning predictive model with 4 biomarkers was developed to accurately classify disease class; the cross-validation results for the merged data set yielded accuracy of 87% and an area under the receiver operating characteristic curve of 93%.CONCLUSIONS: Serum biomarkers hold significant promise for the early, noninvasive detection of EAC.

KW - Biomarker

KW - Early detection

KW - Esophageal adenocarcinoma

KW - Monitoring

KW - Protein

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=84919347969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919347969&partnerID=8YFLogxK

U2 - 10.1002/cncr.28963

DO - 10.1002/cncr.28963

M3 - Article

C2 - 25100294

AN - SCOPUS:84919347969

VL - 120

SP - 3902

EP - 3913

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 24

ER -